Zydus Lifesciences Drug Patent Portfolio
Zydus Lifesciences owns 1 orange book drug protected by 1 US patent Given below is the list of Zydus Lifesciences's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10925871 | Pharmaceutical compositions of sitagliptin | 25 Feb, 2035 | Active |
Latest Legal Activities on Zydus Lifesciences's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Zydus Lifesciences.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Recordation of Patent Grant Mailed
Critical
| 23 Feb, 2021 | US10925871 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Feb, 2021 | US10925871 |
|
Email Notification
Critical
| 04 Feb, 2021 | US10925871 |
|
Issue Notification Mailed
Critical
| 03 Feb, 2021 | US10925871 |
| Dispatch to FDC | 25 Jan, 2021 | US10925871 |
| Dispatch to FDC | 22 Jan, 2021 | US10925871 |
|
Issue Fee Payment Verified
Critical
| 19 Jan, 2021 | US10925871 |
|
Application Is Considered Ready for Issue
Critical
| 19 Jan, 2021 | US10925871 |
|
Issue Fee Payment Received
Critical
| 19 Jan, 2021 | US10925871 |
|
Issue Fee Payment Verified
Critical
| 18 Jan, 2021 | US10925871 |
|
Mail Response to 312 Amendment (PTO-271)
Critical
| 30 Dec, 2020 | US10925871 |
|
Email Notification
Critical
| 30 Dec, 2020 | US10925871 |
|
Response to Amendment under Rule 312
Critical
| 23 Dec, 2020 | US10925871 |
|
Amendment after Notice of Allowance (Rule 312)
Critical
| 21 Dec, 2020 | US10925871 |
| Mail PUB other miscellaneous communication to applicant | 19 Nov, 2020 | US10925871 |
Zydus Lifesciences's Family Patents
Recent FDA approvals and tentative approvals for Zydus Lifesciences
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Empagliflozin; Linagliptin; Metformin Hydrochloride |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 25 Nov, 2025 |
| Olaparib |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 06 Nov, 2025 |
| Carbidopa; Leodopa |
ORIG-2
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 08 Aug, 2025 |
Zydus Lifesciences Drug List
Given below is the complete list of Zydus Lifesciences's drugs and the patents protecting them.
1. Zituvio
Zituvio is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10925871 | Pharmaceutical compositions of sitagliptin |
25 Feb, 2035
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zituvio's drug page